Pfizer drops phase 2 diabetes drug, two earlier-stage candidates

Pfizer has quietly dropped three drug candidates from its pipeline.

During its financials posted today, Pfizer quietly updated its pipeline showing that it has dropped three candidates from its testing programs, but as always, details were thin on the ground.

Its most advanced prospective med from this list was its Type 2 diabetes drug PF-06291874, a glucagon receptor antagonist that finished a midstage test last year.

According to clinicaltrials.gov, Pfizer was testing the drug in over 200 patients against placebo in a three-month study in Type 2 diabetics who couldn’t control their sugar levels using metformin. The study was completed in fall of last year, but data were not made available on the site.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Pfizer also ditched two phase 1 studies for PF-06815345, a small molecule that was aimed at hyperlipidemia, and PF-06412562, for an unspecified cognitive disorder, within its pain and neuroscience division.

Again, looking to clinicaltrials.gov, Pfizer had been testing the latter compound in schizophrenia, with the study being completed in October of last year. 

Read more on

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.